[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Astellas Pharma Korea, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100637278","a-study-to-track-the-safety-of-vesomni-in-men-in-south-korea-treated-in-routine-clinical-practice-for-the-urinary-symptoms-of-benign-prostatic-hyperplasia-enlarged-prostate-100637278",false,"NCT07619105","A Study to Track the Safety of Vesomni in Men in South Korea Treated in Routine Clinical Practice for the Urinary Symptoms of Benign Prostatic Hyperplasia (Enlarged Prostate)","Post-marketing Observational Study for Vesomni Modified Release Tablet 6 mg\u002F0.4 mg (Solifenacin Succinate\u002FTamsulosin Hydrochloride) in Male Patients With Moderate to Severe Storage Symptoms and Voiding Symptoms Associated With BPH Who Are Not Adequately Responding to Treatment With Tamsulosin Monotherapy in South Korea","Inclusion Criteria:\n\n* A patient (adult male) who receives treatment with Vesomni, according to the approved local label during the registration period.\n\nExclusion Criteria:\n\n* A patient with any contraindication for Vesomni, according to the approved local label.\n* A patient who enrolled or is planning to enroll in any study of an investigational medicine during the observation period.","MALE","19 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","Benign prostatic hyperplasia (BPH), also known as an enlarged prostate, happens more often in men as they age. This condition causes a sudden need to pass urine, which is hard to control. Men with an enlarged prostate may need to pass urine many times during the day and night which can affect their wellbeing. There are treatments available, like tamsulosin but they don't work well in some men and can cause further health problems. Vesomni is approved in South Korea to treat urinary symptoms in men with an enlarged prostate, when treatment with tamsulosin doesn't work well enough.\n\nThis study will track the safety of Vesomni given to men in South Korea who have moderate to severe symptoms from an enlarged prostate, who have previously been treated with tamsulosin and found it didn't work well. The safety of Vesomni is tracked by mainly collecting information from their medical records. The sponsor will ask for extra information to be collected, and if any health problems were caused by Vesomni. In this study, researchers want to learn about the safety of Vesomni and how well it controls symptoms in men with an enlarged prostate.\n\nThe men's own doctor decides on treatment, as part of routine clinical practice, not the sponsor (Astellas). This study is about collecting information only. Most information about the safety and control of symptoms will be collected from medical records. The sponsor will also ask for extra information to be collected. All information will be collected for up to 24 weeks after the men start treatment with Vesomni.",[24],"Benign Prostatic Hyperplasia",[26,27,28,29,30,31],"Pollakiuria","Micturition urgency","Voiding Symptoms","Vesomni","Solifenacin succinate","Tamsulosin hydrochloride","NOT_YET_RECRUITING","2026-05-26",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":20},"2026-06-30",{"date":40,"type":20},"2030-11-30",{"name":42,"class":43},"Astellas Pharma Korea, Inc.","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100517008","a-study-to-survey-adults-in-south-korea-with-cancer-who-receive-padcev-injection-100517008","NCT06011954","A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection","Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea","Inclusion Criteria:\n\n* Patients who receive treatment with PADCEV Injection, according to the approved local label.\n\nExclusion Criteria:\n\n* Patients with any contraindication for PADCEV Injection, according to the approved local label.\n* Patients who receive or are going to receive any investigational medicine during the observation period.","ALL",{"count":53,"type":20},202,"Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.\n\nPeople in this study will be adults in South Korea with locally advanced or metastatic urothelial cancer. Metastatic means the cancer has spread to other parts of the body. During their care, the person's doctor will have prescribed PADCEV Injection and other medicines to treat their cancer. People in the study will be treated according to their clinic's standard practice. This study is about collecting information only.\n\nThis study will survey people who know they are receiving PADCEV Injection. The aims of the study are to check outcomes of treatment with PADCEV and record any medical problems during the study.\n\nOnce a doctor has prescribed PADCEV Injection, a person in the study will be observed for up to 48 weeks (about 1 year) after their first dose. During this time, a person's medical records will be reviewed to check for any medical problems and to follow the condition of their cancer. If a person in the study stops taking PADCEV Injection sooner than 48 weeks, records will be reviewed until 30 days (1 month) after each person's last dose of PADCEV Injection or until they start a different medicine for their cancer.",[56],"Urothelial Cancer",[56,58,59,60],"Bladder Cancer","enfortumab vedotin","PADCEV","RECRUITING","2026-05-13",{"date":64,"type":36},"2026-05-14",{"date":66,"type":36},"2023-11-01",{"date":68,"type":20},"2027-07-31",{"name":42,"class":43},18,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100585452","a-study-to-observe-the-safety-of-vyloy-zolbetuximab-in-people-in-south-korea-with-gastric-or-gastroesophageal-junction-cancer-100585452","NCT06902545","A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","Post-marketing Observational Study of VYLOY (Zolbetuximab) Injection 100 mg for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in South Korea","Inclusion Criteria:\n\n* Patients who receive treatment with VYLOY injection, according to the approved local label.\n\nExclusion Criteria:\n\n* Patients with any contraindication for VYLOY injection, according to the approved local label.\n* Patients who are registered or scheduled to be registered in any clinical trials involving investigational drug administration.",{"count":79,"type":20},377,"This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body.\n\nIn South Korea, VYLOY is approved for the treatment of gastric cancer or GEJ cancer. The people in this study will receive VYLOY as part of their usual treatment for their cancer. In standard clinical practice VYLOY is given to people slowly through a tube into a vein.\n\nThe main aim of the study is to collect information in a real-world setting about the safety of VYLOY in people with gastric cancer or GEJ cancer in clinics in South Korea. This study will also help researchers learn how long people's gastric cancer or GEJ cancer stays stable.\n\nThis study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). The study will last about 1 year (54 weeks).",[82,83,84,85],"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma",[87,88,89,85,90,91,92,93],"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma Cancer","Metastatic Gastric Adenocarcinoma Cancer","Claudin 18.2","Human epidermal growth factor receptor 2 (HER2) Negative","zolbetuximab","Pharmcovigilence","2026-03-10",{"date":96,"type":36},"2026-03-11",{"date":98,"type":36},"2025-04-03",{"date":100,"type":20},"2030-07-31",{"name":42,"class":43},13,""]